Methotrexate can influence the central nervous system through several metabolic toxic pathways. These effects can be categorized as immediate, acute to subacute, or chronic neurologic syndromes. The acute to subacute syndrome occurs frequently in acute lymphoblastic leukemia treatment protocols, generally manifesting with focal neurologic signs and changes seen on magnetic resonance imaging and single photon emission computed tomography. While in some patients the neurotoxicity is transient and benign and allows for continuation of chemotherapy, in others it can be quite severe and debilitating, leading to permanent neurologic deficits. The need to modify the treatment protocols when neurotoxicity appears is not fully established. It is also unknown whether the use of sufficient amounts of leucovorin can overcome the toxic effects of the drug. (J Child Neurol 2000;15:573-580).
Get full access to this article
View all access options for this article.
References
1.
Schrappe M., Reiter A., Riehm H:Prophylaxis and treatment of neoplastic meningeosis in childhood acute lymphoblastic leukemia. J Neurooncol1998;38:159-165.
2.
Mahoney DH, Shuster JJ, Nitschke R., et al: Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: An association with intermediate dose intravenous methotrexate and intrathecal triple therapy—A Pediatric Oncology Study Group study. J Clin Oncol1998;16:1712-1722.
3.
Bell B., Abish S., Shuster J., Camitta B:Neurotoxicity (NT) in patients with standard-risk acute lymphoblastic leukemia (ALL) in Pediatric Oncology Group (POG) 9405: A preliminary report . Blood1997;90 (Suppl 1):559A.
4.
Cohen IJ, Vogel R., Matz S., et al: Successful non-neurotoxic therapy (without radiation) of a multifocal primary brain lymphoma with a methotrexate, vincristine and BCNU protocol (DEMOB). Cancer1986;57:6-11.
5.
Griffin TW, Rasey JS, Bleyer WA:The effect of photon irradiation on blood brain barrier permeability to methotrexate in mice. Cancer1977;40:1109-1111.
6.
Ochs JJ:Neurotoxicity due to central nervous system therapy for childhood leukemia. Am JPediatr Hematol Oncol1989;11:93-105.
7.
Wolff L., Zighelboim J., Gale RP:Paraplegia following intrathecal cytosine arabinoside. Cancer1979;43:83-85.
8.
Hwang TL, Yung Wka, Lee YY, et al: High-dose Ara-C-related leukoencephalopathy. J Neurooncol1986;3:335-339.
9.
Bertino JR:"Rescue" techniques in cancer chemotherapy: Use of leucovorin and other rescue agents after methotrexate treatment. Semin, Oncol1977;4:203-216.
10.
Rubnitz JE, Relling MV, Harrison PL, et al: Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia. Leukemia1998;12:1176-1181.
11.
Stark B., Abromov A., Attias D., et al: Successful central nervous system prophylaxis without radiotherapy in childhood acute lymphoblastic leukemia (ALL); Israel National Studies (INS 1984;1989), in: Büchner et al (eds): Acute Leukemias. Vol 4, Prognostic Factors. Berlin, Springer-Verlag , 1994, pp 359-365.
12.
Stark B., Abromov A., Attias D., et al: Extended intrathecal triple therapy for preventing CNS relapse in non-very-high-risk childhood acute lymphoblastic leukemia treated with the Israeli Protocols INS-84 and -89 (modified BFM-86), abstract. Proc Am Soc Clin Oncol1996;15:367.
13.
Balis FM, Poplack DG:Central nervous system pharmacology of antileukemic drugs. Am J Pediatr Hematol Oncol1989;11:74-86.
14.
Bleyer WA, Drake JC, Chabner BA:Neurotoxicity and elevated cerebrospinal fluid methotrexate concentration in meningeal leukemia. N Engl J Med1973;289:770-773.
15.
Surtees R., Clelland J., Hann I:Demyelination and single-carbon transfer pathway metabolites during the treatment of acute lymphoblastic leukemia: CSF studies. J Clin Oncol1998;16: 1505-1511.
16.
Quinn CT, Griener JC, Bottliglieri T., et al: Elevation of homocysteine and excitatory amino acids and neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer . J Clin Oncol1997;15:2800-2806.
17.
Quinn CT, Kamen BA: A biochemical perspective of methotrexate neurotoxicity with insight on nonfolate rescue modalities. J Invest Med1996;44:522-530.
18.
Millot F., Dhond JL, Hayte JM, Bauters F:Impairment of cerebral biogenic amine synthesis in a patient receiving high-dose methotrexate. Am J Pediatr Hematol Oncol1992 ;14:276-278.
19.
Netter JC, Dhondt JL, Ranch F., Petrus M:Neurotoxicité précoce du methotrexate a haute dose et déficit en tetrahydrobiopterine . Arch Fr Pediatr1991;48:719-722.
20.
Millot F., Chastagner P., Dhondt J., Soomelet D:Substitutive therapy in a case of methotrexate neurotoxicity, abstract . Eur J Cancer1992;28A: 1935.
21.
Pääkkö E., Vainionpää L., Pyhtinen J., Lanning M:Minor changes on cranial MRI during treatment in children with acute lymphoblastic leukaemia. Neuroradiology1996 ;38:264-268.
22.
Yim YS, Mahoney DH, Oshman DG:Hemiparesis and ischemic changes of the white matter after intrathecal therapy for children with acute lymphoblastic leukemia. Cancer1991;67:2058-2061.
23.
Pihko H., Tyni T., Virkola K., et al: Transient ischemic cerebral lesions during induction chemotherapy for acute lymphoblastic leukemia. J Pediatr1993;123:718-724.
24.
Asato R., Abiyama Y., Ito M., et al: Nuclear magnetic resonance abnormalities of the cerebral white matter in children with acute lymphoblastic leukemia and malignant lymphoma during and after central nervous system prophylactic treatment with intrathecal methotrexate. Cancer1992;70:1997-2004.
25.
Ohmoto Y., Kajiwara K., Kato S., et al: Atypical MRI findings in treatment-related leukoencephalopathy: Case report. Neuroradiology1996;38:128-133.
26.
Osterlundh G., Bjure J., Lannering B., et al: Studies of cerebral blood flow in children with acute lymphoblastic leukemia: Case reports of six children treated with methotrexate examined by single photon emission computed tomography. J Pediatr Hematol Oncol1997;19:28-34.
27.
Gagliano G. , Costanzi J:Paraplegia following intrathecal methotrexate . Report of a case and review of the literature. Cancer1975;37: 1663- 1668.
28.
Lee Acw, Wong KW, Fong KW, So KT:Intrathecal methotrexate overdose. Acta Paediatr1997;86:434-437.
29.
Winick NJ, Bowman WP, Kamen BA, et al: Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. J Natl Cancer Inst1992;84:252-256.
30.
Packer RJ, Rorke LB, Lange BJ, et al: Cerebrovascular accidents in children with cancer. Pediatrics1985;76:194-201.
31.
Packer RJ, Zimmermann RA, Rosenstock J., et al: Focal encephalopathy following methotrexate therapy. Arch Neurol1981;38:450-452.
32.
Maytal J., Grossman R., Yusuf FH, et al: Prognosis and treatment of seizures in children with acute lymphoblastic leukemia. Epilepsia1995;36:831-836.
33.
Ochs J., Mulhern R., Fairbough D., et al: Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: A prospective study. J Clin Oncol1991; 9:145-151.
34.
Copeland DR , Moore BD Iii, Francis DJ, et al: Neuropsychologic effects of chemotherapy on children with cancer: A longitudinal study. J Clin Oncol1996;14:2826-2835.
35.
Butler RW, Hill JM, Steinheutz PG, et al: Neuropsychologic effects of cranial irradiation, intrathecal methotrexate and systemic methotrexate in childhood cancer. J Clin Oncol1994;12: 2621-2629.
36.
Chien LT, Aur Rja, Verzosa MS, et al: Progression of methotrexate-induced leukoencephalopathy in children with leukemia. Med Pediatr Oncol1981;9:133-141.
37.
Ueberall MA , Wenzel D., Hertzberg H., et al: CNS late effects after ALL therapy in childhood. Part II: Conventional EEG recordings in asymptomatic long-term survivors of childhood ALL-an evaluation of the interferences between neurophysiology, neurology, psychology and CNS morphology. Med Pediatr Oncol1997; 29:121-131.
38.
Harila-Saari A., Vainionpää LK, Kovala TT, et al: Nerve lesions after therapy for childhood acute lymphoblastic leukemia. Cancer1998;82:200-207.
39.
Vainionpää L., Kovala T., Tolonen U., Lanning M:Chemotherapy for acute lymphoblastic leukemia may cause subtle changes of the spinal cord detectable by somatosensory evoked potentials. Med Pediatr Oncol1997;28:41-47.
40.
Cohen IJ, Stark B., Kaplinski C., et al: Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: A case report and analysis of the literature. Pediatr Hematol Oncol1990;7:79-87.
